Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?

Código QR

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?

William Montgomery,1 Tamas Treuer,2 Wenyu Ye,3 Hai Bo Xue,4 Sheng Hu Wu,4 Li Liu,4 Zbigniew Kadziola,5 Michael D Stensland,6 Haya Ascher-Svanum7 1Global Health Outcomes Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia; 2Neuroscience Research, Eli Lilly and Company, Budapest, Hungary; 3Global...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Montgomery W, Treuer T, Ye W, Xue HB, Wu SH, Liu L, Kadziola Z, Stensl, MD, Ascher-Svanum H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/5605d906b7e540bd83b90fbc0a58c7ff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine
por: Montgomery W, et al.
Publicado: (2015)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Takahashi M, et al.
Publicado: (2012)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum H, et al.
Publicado: (2014)

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
por: &Uuml;nsal C, et al.
Publicado: (2013)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki K, et al.
Publicado: (2017)

Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
por: Yang F, et al.
Publicado: (2018)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri H, et al.
Publicado: (2018)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
por: Citrome L, et al.
Publicado: (2019)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Rosaria Di Lorenzo, et al.
Publicado: (2010)

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Chinese subpopulation analysis of a double-blind, randomized, placebo-controlled study
por: Wang G, et al.
Publicado: (2016)

Sex differences in the course of schizophrenia across diverse regions of the world
por: Novick D, et al.
Publicado: (2016)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
por: Adel Gabriel
Publicado: (2010)

Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study
por: Strzelecki D, et al.
Publicado: (2015)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum H, et al.
Publicado: (2012)

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
por: Liang Y, et al.
Publicado: (2017)

A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia
por: Suzuki H, et al.
Publicado: (2013)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao K, et al.
Publicado: (2013)

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia
por: Chen L, et al.
Publicado: (2013)

Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients
por: Ann E Maloney, et al.
Publicado: (2010)

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
por: Giorgio L Colombo, et al.
Publicado: (2008)

Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
por: Katagiri H, et al.
Publicado: (2018)

Olanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group
por: Xu L, et al.
Publicado: (2015)

Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China
por: Wu J, et al.
Publicado: (2015)

A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
por: Manit Srisurapanont, et al.
Publicado: (2021)

Successful Treatment of Delusional Infestation with Olanzapine Depot
por: Javor Vouk-Kamenski, et al.
Publicado: (2021)

Erratum:&nbsp;An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967&ndash;976
por: Colombo GL, et al.
Publicado: (2009)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study
por: Wani RA, et al.
Publicado: (2015)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
por: Ciudad A, et al.
Publicado: (2013)

What if it was easier to prevent schizophrenia than to treat it?
por: Kristen J. Brennand
Publicado: (2017)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
por: Wani RA, et al.
Publicado: (2015)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: JP Lindenmayer
Publicado: (2010)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews M, et al.
Publicado: (2019)

Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review
por: Treuer T, et al.
Publicado: (2016)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
por: An, et al.
Publicado: (2015)

Activation of IL-8 and its participation in cancer in schizophrenia patients: new evidence for the autoimmune hypothesis of schizophrenia
por: Xu LZ, et al.
Publicado: (2018)

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
por: Hong Liu-Seifert, et al.
Publicado: (2009)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang F, et al.
Publicado: (2015)

The Value of Serum Adiponectin in Osteoporotic Women: Does Weight Have an Effect?
por: Ali B. Roomi, et al.
Publicado: (2021)

Quality of life of patients with schizophrenia treated in foster home care and in outpatient treatment
por: Mihanović M, et al.
Publicado: (2015)

Underestimated factors may also precipitate delirium and can lead to the misinterpretation of frailty in these patients
por: İlhan B, et al.
Publicado: (2016)